PET/CT with long field of view

正电子发射断层扫描（PET）通过使用放射性标记示踪剂（放射性药物），能够以高灵敏度和特异性检测体内代谢变化，这些示踪剂可以特异性检测不同疾病的代谢变化或针对特定目标结构（抗原或受体）。PET被认为是最准确的无创评估体内时空代谢变化的方法。与目前可用的设备（FOV为25厘米）相比，所要求的PET/CT扫描仪具有1米的轴向视野（FOV），因此灵敏度将提高10倍，空间和时间分辨率也将大大提高。因此，即使与视场为2米的类似原型相比，也可以实现以前未达到的检测分子变化的图像质量。因此，新的PET/CT检查程序可以进行并进一步开发，这是目前可用技术无法实现的：•超快速全身PET检查（1-2分钟，而不是20分钟），使用不变的放射性药物量•超低剂量PET检查，非常低的辐射暴露（0.5 mSv，而不是6-12 mSv），•高分辨率动态全身PET用于代谢过程的量化•超晚期PET成像（在放射性示踪剂注射后具有高延迟）用于更准确地评估人体生物过程和描述体内药代动力学。我们认为这种新设备是分子成像的里程碑。由于其独特的灵敏度和特异性，在各个领域开辟了全新的研究机会：•开发和测试新的（无线电）药物；所要求的具有放大视场的PET/CT为提高肿瘤疾病诊断和治疗控制的精确度提供了新的机会，并为我们的卓越iFIT（图像引导和功能指导肿瘤治疗）集群提供了非常大的协同作用，目的是个性化控制复杂的肿瘤联合治疗。•癌症患者免疫成像领域的全新研究方法；个体预测或早期治疗分层：个性化免疫治疗是否成功，是否具有显著的社会经济节约潜力•人工智能多参数图像分析（与马克斯普朗克研究所合作）；基于人工智能的动态pet成像评估提供了最准确的代谢变化表征，例如在肿瘤学、神经学、慢性炎症和心血管疾病中的代谢变化•研究极低辐射暴露的非肿瘤学疾病的代谢变化

Positron-Emission-Tomography (PET) enables the detection of metabolic changes in vivo with high sensitivity and specificity, by using radiolabelled tracers (radiopharmaceuticals), which can specifically detect metabolic changes of different diseases or are directed against specific target structures (antigens or receptors). PET is considered to be the most accurate method for the non-invasive assessment of spatial and temporal metabolic changes in vivo. The requested PET/CT scanner has a significantly larger axial field of view (FOV) of 1 m compared to cur-rently available devices (FOV 25 cm), and thus will come with a 10-fold higher sensitivity as well as a considerably improved spatial and temporal resolution. Therefore, a previously unattained image quality for the detection of molecular changes can be achieved, even in comparison with a similar prototype with a FOV of 2 m. Thus, novel examination procedures with PET/CT can be carried out and further developed, which are not possible with the currently available technology:• Ultra-fast whole-body PET-examinations (1-2 min instead of 20 min), with unchanged amount of radiopharmaceuticals administered• Ultra-low dose PET examinations with very low radiation exposure (0.5 mSv instead of 6-12 mSv), as the higher sensitivity enables a considerable reduction in the amount of radiopharmaceuticals ad-ministered • High-resolution dynamic whole-body PET for the quantification of metabolic processes• Ultra-late PET imaging (with high latency after radiotracer injection) for a more accurate assessment of biological processes in humans and description of pharmacokinetics in vivoWe consider this new device as a milestone in molecular imaging, as the unique sensitivity and specificity opens up completely new research opportunities in various fields:• Development and testing of new (radio)pharmaceuticals; the requested PET/CT with enlarged FOV opens new opportunities for enhanced precision in diagnostics and therapy control in oncological diseases with very large synergies for our Cluster of excellence iFIT (image guided and Functionally Instructed Tumor therapies), with the aim of personalized control of complex oncological combination therapies.• Completely new research approaches in the field of immune imaging in cancer patients; individual prediction or early therapy stratification whether a personalized immune therapy is successful with significant economic savings potential for society • Multiparametric image analysis by artificial intelligence (cooperation with Max Planck Institute); AI-based evaluation of dynamic PET-imaging provides the most accurate representation of metabolic changes, e.g., in oncological, neurological, chronic inflammatory and cardiovascular diseases• Investigation of metabolic changes in non-oncological diseases with very low radiation exposure